Objectives: Galectin-3 (Gal-3) is involved in cardiac inflammation and fibrosis, and is in use
as a biomarker that indicates increased risk in heart failure. This study examined the …

Abstract Background: Galectin-3 (Gal-3) is implicated in cardiac fibrosis, but its association
with adverse outcomes after myocardial infarction (MI) is unknown. Objectives: The purpose …

Background: Galectin-3 (Gal-3) is a biomarker involved in a wide range of diseases
including cardiac remodeling following acute myocardial infarction (AMI). Identification of …

Abstract Background Galectin-3 (GAL-3) plays a regulatory role in several diverse biological
processes and disease states. It is associated with heart failure and increased risk of death …

Background: Galectin-3, a biomarker associated with fibrosis and inflammation, has been
implicated in development and progression of heart failure (HF) and predicts increased …

Myocardial infarction (MI) is the most serious manifestation of coronary artery disease and
the cause of significant mortality and morbidity worldwide. Galectin-1 (GAL-1), a divalent …

Background The relationship between galectin-3 (Gal-3) and coronary artery disease (CAD)
has not been fully elucidated. Aim This study aimed to determine the relationship between …

Objective Galectin-3 is a pro-infl ammatory, pro-fi brotic molecule implicated in the
pathogenesis of heart failure, and associated with poor prognostic outcome. When …

Background and Aims Galectin 3 (Gal 3) is a β-galactoside-binding lectin known to play a
part in inflammation, adverse remodeling and fibrosis. Gal 3 seems to be linked to …

Galectin-3 (Gal-3) is a new independent risk factor in the development and severity of
coronary artery disease (CAD). The aim of the study was to evaluate whether Gal-3 …